Das Unternehmen gibt den/die erste behandelte(n) Patient:in in einer klinischen Studie der Phase 1/1b bekannt, in der das neuartige IL-2-Zytokins DF6215 untersucht wird – das siebte von Dragonfly entwickelte Medikament, das in klinische Studien eingetreten ist. WALTHAM, Massachusetts, 6….
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.